- Home
- EOLS
EOLS
Evolus Inc.
as 07-05-2024 2:32pm EST
Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.
| Founded: | 2012 | Country: | United States |
| Employees: | N/A | City: | NEWPORT BEACH |
| Market Cap: | 681.2M | IPO Year: | 2018 |
| Target Price: | $22.60 | AVG Volume (30 days): | 606.9K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.04 | EPS Growth: | N/A |
| 52 Week Low/High: | $7.07 - $15.43 | Next Earning Date: | 07-31-2024 |
| Revenue: | $219,697,000 | Revenue Growth: | 40.45% |
| Revenue Growth (this year): | 32.53% | Revenue Growth (next year): | 33.86% |
Stock Insider Trading Activity of Evolus Inc. (EOLS)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| MOATAZEDI DAVID | EOLS | See Remarks | Jun 4 '24 | Sell | $12.73 | 140,214 | $1,784,685.86 | 533,349 | SEC Form 4 |
| MOATAZEDI DAVID | EOLS | See Remarks | Jun 4 '24 | Sell | $12.92 | 155,278 | $2,006,455.73 | 533,349 | SEC Form 4 |
| MOATAZEDI DAVID | EOLS | See Remarks | Jun 4 '24 | Sell | $12.59 | 175,940 | $2,214,486.40 | 533,349 | SEC Form 4 |
| Malik Vikram | EOLS | Director | Jun 3 '24 | Sell | $12.96 | 7,500 | $97,203.00 | 246,514 | SEC Form 4 |
| GILL DAVID N | EOLS | Director | May 13 '24 | Sell | $12.72 | 3,643 | $46,356.08 | 40,682 | SEC Form 4 |
| GILL DAVID N | EOLS | Director | May 13 '24 | Sell | $12.60 | 6,718 | $84,653.52 | 33,964 | SEC Form 4 |
| Malik Vikram | EOLS | Director | May 13 '24 | Sell | $12.93 | 28,000 | $362,012.00 | 254,014 | SEC Form 4 |
| Avelar Rui | EOLS | See Remarks | May 10 '24 | Sell | $12.72 | 3,441 | $43,760.57 | 368,847 | SEC Form 4 |
| Beaver Sandra | EOLS | Chief Financial Officer | May 10 '24 | Sell | $12.72 | 2,423 | $30,814.26 | 151,778 | SEC Form 4 |
| MOATAZEDI DAVID | EOLS | See Remarks | May 10 '24 | Sell | $12.72 | 16,051 | $204,126.99 | 673,563 | SEC Form 4 |
| MOATAZEDI DAVID | EOLS | See Remarks | Mar 27 '24 | Sell | $13.86 | 6,236 | $86,430.96 | 689,614 | SEC Form 4 |
| Beaver Sandra | EOLS | Chief Financial Officer | Mar 19 '24 | Sell | $13.92 | 5,672 | $78,978.06 | 154,201 | SEC Form 4 |
| Avelar Rui | EOLS | See Remarks | Mar 19 '24 | Sell | $13.92 | 27,603 | $384,349.69 | 372,288 | SEC Form 4 |
| MOATAZEDI DAVID | EOLS | See Remarks | Mar 19 '24 | Sell | $13.92 | 96,566 | $1,344,604.30 | 695,850 | SEC Form 4 |
| MOATAZEDI DAVID | EOLS | See Remarks | Feb 21 '24 | Sell | $13.08 | 7,706 | $100,803.73 | 792,416 | SEC Form 4 |
| Avelar Rui | EOLS | See Remarks | Feb 21 '24 | Sell | $13.08 | 1,821 | $23,820.87 | 399,891 | SEC Form 4 |
| Beaver Sandra | EOLS | Chief Financial Officer | Feb 21 '24 | Sell | $13.08 | 1,821 | $23,820.87 | 159,873 | SEC Form 4 |
| Parschauer Karah Herdman | EOLS | Director | Jan 30 '24 | Sell | $13.14 | 11,931 | $156,732.77 | 31,243 | SEC Form 4 |
| MOATAZEDI DAVID | EOLS | See Remarks | Dec 6 '23 | Sell | $10.09 | 51,348 | $517,890.79 | 635,244 | SEC Form 4 |
| MOATAZEDI DAVID | EOLS | See Remarks | Dec 6 '23 | Sell | $9.73 | 31,300 | $304,505.18 | 603,944 | SEC Form 4 |
Latest Evolus Inc. News
EOLS Breaking Stock News: Dive into EOLS Ticker-Specific Updates for Smart Investing
Business Wire
4 days ago
Evolus Announces Appointment of Albert G. White III to Board of Directors
MT Newswires
11 days ago
Evolus Completes FDA Premarket Approval Submission for Evolysse Dermal Fillers for 'Smile Lines'
Business Wire
11 days ago
Evolus Announces Submission of Premarket Approval Application to the U.S. Food and Drug Administration for First Two Evolysse™ Dermal Filler Products
Simply Wall St.
16 days ago
Market Sentiment Around Loss-Making Evolus, Inc. (NASDAQ:EOLS)
Business Wire
23 days ago
Evolus Broadens International Presence with Launch of Nuceiva® (botulinum toxin type A) in Spain
GuruFocus.com
a month ago
Insider Sale: Director Carol Lowe Sells Shares of EMCOR Group Inc (EME)
ACCESSWIRE
a month ago
Camber Energy Announces Passing of Director Lawrence Fisher
GlobeNewswire
a month ago
ThreeD Capital Inc. Announces Unaudited May 31, 2024 Net Asset Value Per Share - $0.72
Share on Social Networks:
Disclaimer
The information presented on this page, "EOLS Evolus Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.